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AD, Alzheimer’s disease; Aldh2, aldehyde dehydrogenase 2; APP, amyloid precursor 
protein; BAD, BCL-2 associated agonist of cell death; Bdnf, brain-derived neurotrophic 
factor; CaMKII, calcium calmodulin kinase II; CaN, calcineurin; CDK5, cyclin dependent 
kinase; cDNA, complementary DNA; CREB, cAMP response element-binding; Ct, cycle 
threshold; Cxcl-10, C-X-C motif chemokine ligand 10; (EAAT)2, cxcitatory aminoacid 
transporter 2; ERK, cxtracellular signal–regulated Kinase; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; GFAP, glial fibrillary acid protein; GSK3β, glycogen synthase 
kinase 3β; H2O2, hydrogen peroxide; Hmox 1, hemoxygenase 1; I2-IR, imidazoline 2 
receptors; Ide, insulin degrading enzyme; Ifnγ, interferon-γ; iNOS, inducible nitric oxide 
synthase; LTD, long-term depression; LTP, long-term potentiation; MAO, 
Monoamineoxidase; mRNA, messenger RNA; Nep, neprilysin;  NFATc1, nuclear factor of 
activated T-cells Cytoplasmic 1; NMDA, N-Methyl-D-aspartate; NMDAR, N-Methyl-D-
aspartate receptor; NORT, novel object recognition test; Nrf1, nuclear factor-erythroid2-
related factor 1; OFT, open field test; OS, oxidative stress; p-Tau, hyperphosphorylated 
Tau; PD, Parkinson’s disease; PKA, protein kinase A; PP2B, phosphatase 2B; PVDF, 
polyvinylidene difluoride; ROS, reactive oxygen species; qPCR, real-time quantitative 
PCR; RT-PCR, reverse transcription-polymerase chain reaction; SAMP8, senescence-
accelerated mouse prone 8; sAPPα, soluble APP α; sAPPβ, soluble APP β; SDS-PAGE, 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis; SEM, standard error of the 
mean; TBS-T, tween 20 TBS; TBS, tris-buffered saline; TN, novel object, new location; 
Tnf-α, tumor necrosis factor alpha; TO, old object, old location; TrkB, tropomyosin-related 




































































Brain aging and dementia are current problems that must be solved. The levels of 
imidazoline 2 receptors (I2-IRs) are increased in the brain in Alzheimer’s disease (AD) and 
other neurodegenerative diseases. We tested the action of the specific and selective I2-IR 
ligand B06 in a mouse model of accelerated aging and AD, the senescence-accelerated 
mouse prone 8 (SAMP8) model. Oral administration of B06 for four weeks improved 
SAMP8 mouse behavior and cognition and reduced AD hallmarks, oxidative stress, and 
apoptotic and neuroinflammation markers. Likewise, B06 regulated glial excitatory amino 
acid transporter 2 and N-methyl-D aspartate 2A and 2B receptor subunit protein levels. 
Calcineurin (CaN) is a phosphatase that controls the phosphorylation levels of cAMP 
response element-binding (CREB), apoptotic mediator BCL-2-associated agonist of cell 
death (BAD) and GSK3β, among other molecules. Interestingly, B06 was able to reduce 
the levels of the CaN active form (CaN A). Likewise, CREB phosphorylation, BAD gene 
expression, and other factors were modified after B06 treatment. Moreover, 
phosphorylation of a target of CaN, nuclear factor of activated T-cells, cytoplasmic 1 
(NFATC1), was increased in B06-treated mice, impeding the transcription of genes related 
to neuroinflammation and neural plasticity. In summary, this I2 imidazoline ligand can exert 
its beneficial effects on age-related conditions by modulating CaN pathway action and 
affecting several molecular pathways, playing a neuroprotective role in SAMP8 mice. 
 
1. Introduction 
Aging has become a problem worldwide, since older people are more prone to develop 
chronic and degenerative diseases. At the brain level, aging affects several molecular 
pathways that predispose patients to neurodegeneration, causing dementia, cognitive 
impairment and loss of quality of life. Among dementias, the most prevalent is Alzheimer’s 
disease (AD) (GBD 2016 Neurology Collaborators, 2019). AD has aroused considerable 
interest because of its strong influence on quality of life among elderly individuals and 




































































β-Amyloid deposition in senile plaques and tau hyperphosphorylation forming 
neurofibrillary tangles are specific hallmarks of AD (Serrano-Pozo et al. 2011). However, 
there are no successful pharmacological treatments that modify the progression of AD, 
given that acetylcholinesterase inhibitors and memantine fail to stop the progression of 
dementia (Cummings et al. 2014, Cummings et al. 2018). Apart from the use of approved 
drugs, several clinical attempts have been made to treat AD progression by using various 
other strategies, such as immunotherapy against β-amyloid and beta-secretase (BACE) 
inhibitor administration, but the results have been disappointing (Cummings et al. 2018). 
These results show that addressing only the “β-amyloid cascade hypothesis” cannot fully 
control the progression of the disease, and this hypothesis also cannot explain the advanced 
neuronal damage in AD. Therefore, identifying new pharmacological targets for AD 
treatment is an active area of research. 
 
In most neurodegenerative processes, including AD, neuroinflammation and oxidative 
stress (OS) are common traits. It is well-accepted that Ca2+ dysfunction is a consequence of 
homeostatic imbalance in nerve cells that unleashes a string of molecular and cellular 
processes, including neuroinflammation, OS, changes in neuronal plasticity, differential 
expression of glutamate and cholinergic receptors, and amyloid pathology (Sompol and 
Norris. 2018). Together, these processes end with cognitive decline and neurodegeneration. 
Calcineurin (CaN), also known as protein phosphatase 2B, is a Ca2+-dependent Ser/Thr 
phosphatase that is highly abundant in the brain, appearing at high levels in neurons and 
low levels in glia in healthy adult animals (Kuno et al. 1992). CaN is related to long-term 
potentiation (LTP) and long-term depression (LTD), and dysregulation of CaN has been 
linked with cognitive loss in an AD mouse model (Baumgärtel & Mansuye. 2012; Reese 
LC and Taglialatela G. 2011). Of importance, CaN levels and signaling are increased in the 
cortex in AD patients (Wu et al. 2010) and in the contexts of other human 
neurodegenerative pathologies, including Parkinson’s disease (PD) (Caraveo et al. 2014), 
Lewy body aggregation (Martin et al. 2012), and vascular pathology (Pleiss et al. 2016b). 
Moreover, CaN activity prevents fear memory formation in the amygdala by 
dephosphorylating and inhibiting downstream kinases, including AKT and extracellular 


































































(Wang et al. 2018; Mulkey et al. 1994) and glycogen synthase kinase 3β (GSK3β) 
(Watanabe et al. 2015) are some of the key actors in central nervous system function that 
are controlled by the phosphatase activity of CaN, which in turn is controlled by calcium 
calmodulin kinase II (CaMKII) and intracellular Ca2+ levels (Bezprozvanny and Hiersinger. 
2013). Nuclear factor of activated T-cells (NFAT) consists of at least two different 
components, one with nuclear localization and one that is phosphorylated and localized in 
the cytoplasm (Horsley and Pavlath. 2002). Furthermore, recently, the CaN pathway has 
been observed to link astrocytic Ca2+ dysregulation to neuroinflammation, glutamate, β-
amyloid accumulation and synaptotoxicity (Sompol and Norris. 2018). 
 
Imidazoline 2 receptors (I2-IRs) (Bousquet et al. 2020) are increased in AD brains (Ruiz J 
et al. 1993; García-Sevilla et al. 1998), and radioactive ligands have been studied as 
biomarkers for AD and PD progression in patients (Tyacke et al. 2018; Wilson et al. 2019). 
There is evidence that I2-IR ligands reduce neurodegenerative processes, including 
cognitive decline, neuroinflammation, OS and AD hallmarks, but less is known about the 
upstream mechanism involved in the beneficial effects of I2-IR modulation. Thus, the 
objective of this work was to delineate the molecular mechanisms involved in the 
neuroprotective effect of I2-IR modulation in a mouse model of AD linked to the aging 
process, the senescence-accelerated mouse prone 8 (SAMP8) model. To this end, we used a 
newly synthesized I2-IR ligand, diethyl (1RS,3aSR,6aSR)-5-(3-chloro-4-fluorophenyl)-4,6-
dioxo-1-phenyl-1,3a,4,5,6,6a-hexahydropyrrolo[3,4-c]pyrrole-1-phosphonate, named B06, 
which has outstanding affinity and selectivity for I2-IRs over α2 adrenoreceptors (Escolano 
et al. 2019). 
The SAMP8 strain is a nontransgenic mouse strain established through phenotypic 
selection of the AKR/J mouse strain and is an attractive model with which to study aging 
processes, especially age-related deterioration of learning and memory, emotional disorders 
and neurochemical alterations (Takeda et al. 2009, Pallas. 2012). At approximately 5 
months of age, the mice begin to undergo an accelerated process of senescence, and the 
brain aging manifests as severe cognitive decline and neuroinflammation (Akiguchi et al. 
2017). It is considered a late-onset AD mouse model characterized by altered amyloid 


































































et al. 2005; Morley et al., 2012). Moreover, inflammatory and OS markers are present at 




2.1 In vivo studies in mice 
Twelve-month-old female SAMP8 mice (n = 23) (Envigo, Sant Feliu de 
Codines,Barcelona, Spain)) were used to carry out cognitive and molecular analyses. The 
animals were randomly allocated into two experimental groups: the SAMP8 control group 
(control) (n=12), which was administered vehicle (2-hydroxypropyl)-β-cyclodextrin 1.8% 
in drinking water, and the SAMP8 group, which was treated with the I2-IR ligand B06 (5 
mg/kg) (n=11). The animals had free access to food and water and were kept under 
standard temperature conditions (22 ± 2°C) and 12-hour/12-hour light/dark cycles (300 
lux/0 lux). B06 (5 mg/kg/day) was diluted in 1.8% (2-hydroxypropyl)-β-cyclodextrin and 
administered through drinking water. After 4 weeks of treatment, behavioral and cognitive 
tests, including short- and long-term memory, were performed to study the effects of 
treatment on learning and memory. Weight and water consumption were controlled each 
week, and the B06 concentration was adjusted accordingly to reach the optimal dose until 
euthanasia. The mice were euthanized 3 days after behavioral test completion by cervical 
dislocation. The brains were immediately removed from the skulls and frozen on powdered 
dry ice. The samples were stored at -80°C until the biochemical experiments. 
The studies and procedures for the mouse behavior tests, brain dissection and extractions 
followed the ARRIVE and standard ethical guidelines (European Communities Council 
Directive 2010/63/EU and Guidelines for the Care and Use of Mammals in Neuroscience 
and Behavioral Research, National Research Council 2003) and were approved by 
Bioethical Committees from the University of Barcelona and the Government of Catalonia. 
All efforts were made to minimize the number of animals used and their suffering. 
 
2.2 Novel object recognition test (NORT) 
Briefly, mice were placed in a 90° two-arm 25-cm-long, 20-cm-high, 5-cm-wide black 


































































10 minutes for 3 days. On day 4, the animals were allowed to freely explore in a 10-minute 
acquisition trial (first trial), for which they were placed in the maze in the presence of two 
identical objects at the end of each arm (Fig. 1A). After a delay (2 h for short-term memory 
evaluation and 24 h for long-term evaluation), the animal was allowed to explore the old 
object and one novel object in each trial (Fig. 1A). The time that the mice spent exploring 
the novel object (TN) and the time that the mice spent exploring the old object (TO) were 
measured. A DI was defined as (TN−TO)/(TN+TO). Exploration of an object was defined 
as pointing the nose towards the object at a distance ≤2 cm and/or touching it with the nose. 
Turning or sitting around the object was not considered exploration. To avoid object 
preference biases, the objects were counterbalanced. 
 
2.3 Open field test (OFT) 
The open field test (OFT) was performed as previously described (Griñán-Ferré et al., 
2015) (Fig. 1B). Briefly, mice were placed at the center of and allowed to explore a white 
plywood box (50x50x25 cm) for 5 minutes. Behavior was scored with SMART® ver. 3.0 
software, and each trial was recorded for later analysis. The parameters scored included the 
center stay duration, number of rearings, number of defecations, and distance traveled. 
 
2.4 Determination of oxidative stress 
Hydrogen peroxide (H2O2) was measured as an indicator of OS, and it was quantified using 
a hydrogen peroxide assay kit (Cat. No. MAK165, Sigma-Aldrich, Saint Louis, Missouri, 
Estats Units) according to the manufacturer’s instructions. 
 
2.5 Immunodetection experiments 
2.5.1. Brain processing 
Three days after the behavioral and cognitive tests, mice were euthanized for protein 
extraction and RNA and DNA isolation. After euthanasia, the brains were immediately 




































































For an IHC experiment, mice were anesthetized (ketamine 100 mg/kg and xylazine 10 
mg/kg, intraperitoneally) and then perfused with 4% paraformaldehyde (PFA) diluted in 0.1 
M phosphate buffer solution intracardially. Their brains were removed and postfixed in 4% 
PFA overnight at 4°C. Afterwards, the solutions were changed to PFA + 15% sucrose. 
Finally, the brains were frozen on powdered dry ice and stored at -80°C until sectioning. 
 
2.5.2 Protein level determination by Western blotting 
For subcellular fractionation, 150 μL of buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 
mM EDTA pH 8, 0.1 mM EGTA pH 8, 1 mM DTT, 1 mM PMSF, protease inhibitors) was 
added to each sample, and the mixtures were incubated on ice for 15 min. After this time, 
the samples were homogenized with a tissue homogenizer, 12.5 μL Igepal 1% was added, 
and the Eppendorf tubes were vortexed for 15 s. Following 30 s of full-speed centrifugation 
at 4°C, the supernatants (cytoplasmic fractions) were collected; 80 μL of buffer C (20 mM 
HEPES pH 7.9, 0,4 M NaCl, 1 mM EDTA pH 8, 0.1 mM EGTA pH 8, 20% glycerol 1 mM 
DTT, 1 mM PMSF, protease inhibitors) was added to each pellet, and the pellets were 
incubated under agitation at 4°C for 15 min. Subsequently, the samples were centrifuged 
for 10 min at full speed at 4°C. The supernatants (nuclear fractions) were collected. 
For Western blotting (WB), aliquots of 20 µg of hippocampal protein were used. Protein 
samples from mice were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) (8-12%) and transferred onto polyvinylidene difluoride 
(PVDF) membranes (Millipore). Afterwards, the membranes were blocked in 5% nonfat 
milk in 0.1% Tris-buffered saline with Tween 20 (TBS-T) for 1 hour at room temperature 
before being incubated overnight at 4°C with the primary antibodies listed in Table 1. 
The membranes were washed and incubated with secondary antibodies for 1 hour at room 
temperature. Immunoreactive proteins were viewed with a chemiluminescence-based 
detection kit following the manufacturer's protocol (ECL Kit; Millipore, Burlington, 
Massachusetts, USA), and digital images were acquired using a ChemiDoc XRS+ System 
(Bio-Rad, Hercules, California, USA). Semiquantitative analyses were carried out using 
ImageLab software (Bio-Rad), and the results are expressed in arbitrary units (AU), with 
the control protein levels set as 100%. Protein loading was routinely monitored by 




































































Brain coronal sections of 30 μm were obtained (Leica Microsystems CM 3050S cryostat, 
Wetzlar, Germany) and kept in a cryoprotectant solution at -20°C until use. Free-floating 
slices were placed in a 24-well plate and washed with 0.01 M PBS + 1% Triton X-100. 
Next, the free-floating sections were blocked with a solution containing 5% fetal bovine 
serum (FBS), 1% Triton X-100, 0.01 M PBS + gelatin 0.2% for 2 h at room temperature; 
washed with PBST (PBS 0.1 M, 1% Triton X-100) five times for 5 min each; and incubated 
with the primary antibodies listed in Table 2 overnight at 4°C. On the following day, the 
coronal slices were washed with PBST 6 times for 5 min each and then incubated with the 
secondary antibodies listed in Table 2 at room temperature for 2 h. Later, the sections were 
coincubated with 5 M Hoechst staining solution (Sigma-Aldrich,) for 5 min in the dark at 
room temperature and washed with 0.01 M PBS. Finally, the slices were mounted using 
Fluoromount-G (EMS, Hatfield, Pennsylvania, USA), and image acquisition was 
performed with a fluorescence laser microscope (Olympus BX41, Hamburg, Germany) by 
using x4 and x10 magnification. At least four images from 4 different individuals in each 
group were analyzed with ImageJ/Fiji software available online from the National Institutes 
of Health. 
 
2.6 RNA extraction and gene expression determination 
Total RNA isolation was carried out using TRIzol® reagent according to the manufacturer’s 
instructions. The yield, purity, and quality of RNA were determined spectrophotometrically 
with a NanoDrop™ ND-1000 apparatus (Thermo Scientific, Waltham, 
Massachusetts,USA) and an Agilent 2100B Bioanalyzer (Agilent Technologies, Santa 
Clara, California, USA). RNA samples with 260/280 ratios and RINs higher than 1.9 and 
7.5, respectively, were selected. Reverse transcription-polymerase chain reaction (RT-PCR) 
was performed. Briefly, 2 μg of messenger RNA (mRNA) was reverse-transcribed using a 
high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, California, 
USD). 
SYBR® Green real-time PCR was performed on a StepOnePlus Detection System (Applied 


































































mixture contained 6.75 μL of complementary DNA (cDNA) (with a concentration of 2 μg), 
0.75 μL of each primer (with a concentration of 100 nM), and 6.75 μL of SYBR® Green 
PCR master mix (2X). 
TaqMan-based real-time PCR (Applied Biosystems) was also performed in a StepOnePlus 
Detection System (Applied Biosystems). Each 20 μL TaqMan reaction contained 9 μL of 
cDNA (25 ng), 1 μL of 20X TaqMan gene expression assay probe and 10 μL of 2X 
TaqMan universal PCR master mix. 
The data were analyzed utilizing the comparative cycle threshold (Ct) (ΔΔCt) method, in 
which the levels of a housekeeping gene are used to normalize differences in sample 
loading and preparation. Normalization of expression levels was performed with β-actin for 
SYBR® Green-based real-time PCR and Gapdh for TaqMan-based real-time PCR. The 
primer sequences and TaqMan probes used in this study are presented in Table 3. Each 
sample was analyzed in duplicate, and the results represent the n-fold differences in the 
transcript levels among different groups. 
 
2.7 Statistical analysis 
Statistical analysis was conducted using GraphPad Prism ver. 8 statistical software. The 
data are expressed as the mean ± standard error of the mean (SEM). Means were compared 
with two-tailed Student’s t-test. Statistical significance was considered when p values were 
<0.05. Statistical outliers were determined with Grubbs' test and when necessary were 




3.1 Prevention of memory loss and behavioral impairment in SAMP8 mice after I2-IR 
ligand treatment 
The NORT demonstrated significant differences between the control and I2-IR ligand B06 
groups in both short- and long-term evaluations. Significantly higher DI values were 
obtained for the B06-treated mice than for the control mice at 2 h and 24 h after novel 
object exposure, indicating a neuroprotective action of B06 against the characteristic 


































































In addition, the results regarding locomotor activity, time spent in the center area and 
number of rearings, as assessed with the OFT paradigm, revealed significant changes in 
behavior in the B06 group in comparison with the control group (Figs. 1E-G). 
 
3.2 AD hallmark modifications in the hippocampi of SAMP8 mice induced by I2-IR 
ligand treatment 
The levels of key proteins involved in APP processing were evaluated. The I2-IR ligand 
B06 promoted significant increases in soluble APPα (sAPPα) levels but clearly tended to 
decrease soluble APPβ (sAPPβ) levels (Figs. 2A-B). Accordingly, the gene expression of 
Adam10, a constitutive α-secretase, increased, indicating a shift to the nonamyloidogenic 
pathway (Fig. 2C). Moreover, the gene expression of both insulin-degrading enzyme (Ide) 
and neprilysin (Nep) was increased after B06 treatment (Fig. 2C). 
Tau hyperphosphorylation is a characteristic posttranslational modification in aged SAMP8 
mice. B06 treatment induced significant decreases in phosphorylation at the Ser404 and 
Ser396 sites in tau protein (Figs. 3A-B). There are two main kinases implicated in tau 
hyperphosphorylation: glycogen synthase kinase 3β (GSK3β) and cyclin-dependent kinase 
5 (CDK5). GSK3β phosphorylated at Ser9 is the inactive form of the enzyme and is 
correlated with reduced tau phosphorylation. As expected, the I2-IR ligand B06 increased p-
GSK3β (Ser9) levels, indicating that it reduced kinase activity (Fig. 3C). CDK5 is also 
activated by phosphorylation, and p25, a coactivator, controls its activity. The results 
showed that the I2-IR ligand-treated group presented decreases in the p-CDK5 level and 
p25/p35 ratio (Figs. 3D-E). 
 
3.3 I2-IR ligand treatment changes synaptic and apoptotic markers in SAMP8 mice 
The I2-IR ligand B06 reduced the protein levels of the NMDA 2B receptor, increased those 
of the form phosphorylated at Tyr1472 and increased those of the NMDA 2A receptor 
significantly (Figs. 4A-C). 
The levels of calcium/calmodulin-dependent protein kinase II (CaMKII), a marker of 
synaptic plasticity, did not show significant changes, but the levels of the phosphorylated 


































































4D) in the B06 group. Accordingly, the gene expression of the CREB target brain-derived 
neurotrophic factor (Bdnf) was increased in the B06 group (Fig. 4G). 
Protein kinase A (PKA) is a master regulator of the activity of CREB, among other 
transcription factors. B06-treated animals showed increased protein levels of PKA a (the 
catalytic fragment) (Fig. 4E). We found significant recovery of AKT, also known as protein 
kinase B, phosphorylation and subsequent activation (Fig. 4F) in the B06 group, indicating 
a pathway of neuroprotective regulation after B06 treatment. 
B-cell lymphoma 2 (BCL-2), Bax, BCL-2-associated agonist of cell death (BAD) and 
Caspase 3 are key factors in apoptotic signaling in neurons. B06 was able to reduce 
Caspase 3 and Bcl-2-like protein 4 (Bax) protein levels; surprisingly, it also reduced BCL-2 
protein levels (Figs. 5A-C). An increase in p-BAD was also observed (Fig. 5D); however, 
in this case, phosphorylation of BAD indicated a lack of capacity to form apoptotic pores 
by dimerizing BAD, which subsequently weakened the proapoptotic role of this factor. 
Overall, prevention of apoptotic mechanisms followed treatment with the I2-IR ligand B06. 
 
3.4 Neuroinflammation and oxidative state changes in SAMP8 mice after I2-IR ligand 
treatment 
GFAP protein levels were highly significantly decreased in the B06 group (Fig. 6A), 
indicating that astrogliosis and neuroinflammation processes were ameliorated in I2-IR 
ligand B06-treated mice. Astrocytes control glutamatergic signaling through glutamate 
transporters, and B06 was able to enhance the protein levels of excitatory amino acid 
transporter (EAAT) 2 (Fig. 6B). The expression of proinflammatory cytokines, such as 
interleukin (Il)-6, Il-18, Il-1β, interferon (Ifn)γ, tumor necrosis factor-alpha (Tnf-α), and C-
X-C motif chemokine ligand 10 (Cxcl-10), was decreased after treatment with the I2-IR 
ligand B06 (Fig. 6C), and the decrease reached significance for Il-6, Il-18 and Il-1β. H2O2 
levels in the hippocampus were significantly diminished in the B06 mouse group, showing 
that global redox homeostasis was shifted due to the antioxidant role of the I2-IR ligand in 
SAMP8 mice (Fig. 6D). The expression of nuclear factor-erythroid 2-related factor 1 
(Nrf1), a key gene controlling the oxidative cell environment, was higher in the group 
treated with the I2-IR ligand B06 than in the untreated mouse group (Fig. 6E). In addition, 


































































was increased, whereas that of aldehyde dehydrogenase 2 (Aldh2) was reduced, indicating 
that B06 prevented SAMP8 brain from experiencing an oxidant environment by 
neutralizing radical oxygen species (ROS) (Fig. 6E). Conversely, a significant increase in 
the gene expression of inducible nitric oxide synthase (iNOS) was found, although this 
increase could have improved synaptic function (Fig. 6E). Finally, immunostaining 
quantification of GFAP fluorescence intensity demonstrated that B06 treatment 
significantly reduced GFAP staining, especially in the dentate gyrus (DG) and CA1 regions 
(Figs. 6F-M), suggesting a reduction in astrogliosis. Moreover, immunostaining 
quantification of S100A9 fluorescence intensity showed that B06 treatment reduced 
S100A9 staining, especially in the CA1 and CA3 regions, but the reductions were not 
significant (Figs. 6F-M). 
 
3.5 I2-IR ligand treatment modifies CaN/NFAT signaling in the SAMP8 mouse 
hippocampus 
In light of the obtained results, we focused on CaN, an upstream protein with phosphatase 
activity toward CREB or BAD that plays a role in neurodegeneration. The protein levels of 
CaN A, the active form, were reduced after treatment with the I2-IR ligand B06 (Fig. 7A). 
We also evaluated NFATC1, a different target of CaN. The results showed an increase in the 
phosphorylated form (Fig. 7B). 
As a summary of the results, Figure 8 shows the molecular alterations related to cognitive 
improvement as well as the key role of CaN in controlling the cellular response after 




Here, we report that treatment with the I2-IR ligand B06 in the SAMP8 mouse model, a 
model of neurodegeneration linked to aging that is considered to recapitulate late-onset AD, 
has beneficial effects via modulation of the CaN pathway. Imidazoline receptors were 
described in the nineties, and I2-IRs are related to neurodegenerative diseases such as AD 
(García-Sevilla et al. 1998), Huntington’s disease (Reynolds et al. 1996) and PD (Reynolds 


































































pathway for I2-IR remains elusive (Bousquet et al, 2020). Previous reports have indicated 
putative roles related to monoamine oxidase (MAO) A or B (McDonald et al. 2010) and 
intracellular calcium concentration control through NMDA receptors or intracellular 
calcium stores (Jiang et al. 2010; Zhao Han et al. 2013). Recently, we have demonstrated 
that ligands for I2-IRs are able to prevent neurodegeneration by acting on the apoptotic 
mechanism (Abas et al. 2017), and decreasing the activity of kinases (CDK5, GSK3β, etc.) 
(Abas et al. 2016, Griñán-Ferré et al. 2019), leading to the recovery of cognitive 
capabilities in an AD mouse model (Griñán-Ferré et al. 2019). However, the intrinsic 
mechanisms that induce these changes are not precisely known. 
 
B06 is a new improved I2-IR ligand with a lower Ki for I2-IR than previous ligands and 
high selectivity for I2-IRs over α2 adrenoceptors (Escolano et al. 2019). The latter 
characteristic is of the utmost importance for avoidance of undesirable adverse effects on, 
for example, the vascular system. We have previously reported that administration of B06 
to the 5xFAD mouse model, a transgenic representative model of AD, reduces cognitive 
decline, neuroinflammation, tau hyperphosphorylation and APP processing (Escolano et al. 
2019). 
In the present work, we demonstrated that the I2-IR ligand B06 was able to improve 
cognition and ameliorate anxiety-like behavior in aged SAMP8 mice. Furthermore, we 
confirmed that on the molecular level, treatment with B06 reduced the exhibition of AD 
hallmarks, such as APP processing and tau hyperphosphorylation; inhibited tau kinase 
(CDK5 and GSK3β) activation; reduced the gene expression of neuroinflammation 
markers, such as Il-6, Il-18, and Tnf-α; and decreased OS. 
 
When the apoptotic pathway was studied, decreases in Caspase 3, Bax, and BCL-2 levels 
were found. However, there has been a lack of consistency among I2-IR studies regarding 
the reduction in apoptotic signaling (Garau et al. 2013). Our results are consistent with 
those of several studies showing that administration of I2-IR ligands such as 2-BFI and 
BU224 can reduce apoptotic marker levels in the rat brain cortex (Li. 2017). Considering 
that I2-IRs have been reported to be involved in key pathways associated with 


































































mice, including those that are under the control of cytosolic calcium, astrocyte activation 
and synaptic neural plasticity. The localization of I2-IRs remains elusive, but several studies 
have reported astrocytes as a major cell type with I2-IR binding sites (Choi et al. 2018). Of 
note, astrogliosis and activated microglial cells are associated with amyloid processing, 
indicating that this AD hallmark is a major trigger of gliosis (Vehmas et al. 2003). After 
B06 treatment, a very significant decrease in the expression of the hippocampal 
panastrocytic reactive marker GFAP indicated strong control of neuroinflammation and a 
reduction in astrogliosis that in turn could prevent neuronal function loss. Moreover, 
S100A9, a Ca2+-binding protein with a critical role in modulating the inflammatory 
response and inducing cytokine release by astrocytes (Wang et al. 2018), was used as a 
marker of neuroinflammation mediated by reactive astrocytes. In our study, we found clear 
reductions in two hippocampal areas, CA1 and CA3, confirming a reduction in the 
inflammatory state after treatment with B06. Likewise, the expression of the EAAT2 
isoform (or Glt 1), a glutamate transporter predominantly located in astrocytes, was 
increased after treatment with the I2-IR ligand B06. EAAT2 is implicated in glutamate 
clearance and has a leading role in the removal of excess glutamate and other potentially 
toxic mediators (Furman and Norris. 2014). In line with these findings, our previous results 
for two other I2-IR ligands (Griñán-Ferré et al. 2018) showed the same action regarding 
astrogliosis. However, in contrast, another study on the I2-IR ligand LSL60101 showed 
induction of reactive astrocytosis in the facial motor nuclei of neonate rats after short-term 
treatment (Casanovas et al. 2000), suggesting that the effects differ depending on both the 
physicochemical properties of the I2-IR ligand and the experimental model. 
 
Notably, in astrocytes, increased CaN activity can lead to modification of the kinase 
activity of GSK3β (Watanabe et al. 2015). Calcium entry through NMDA2B receptors 
enhances the activation of GSK3β through CaN phosphatase activity, and in turn, GSK3β 
amplifies this phosphatase activity, dephosphorylating CREB (Szatmari et al. 2005; Wang 
et al. 2018). In addition, the interaction of I2-IR ligands with NMDA receptors has been 
well described (Olmos, De-Gregorio-Rocasolano, et al. 1999; Olmos, Ribera & Garcia-
Sevilla. 1996). Thus, our results support the idea that modulation of I2-IRs by B06 is able to 


































































subunit composition and activation. On the one hand, increases in NMDA2A receptor 
protein levels were observed. On the other hand, decreases in NMDA2B receptor protein 
levels with increased phosphorylation were observed. These changes are associated with 
LTP, which may partially explain the improvement in cognition observed in B06-treated 
SAMP8 mice. 
 
To further elucidate the molecular mechanisms modulated by B06, we examined the 
negative crosstalk between AKT and GSK3β signaling that participates in synaptic 
plasticity (Bradley et al. 2012) controlled by CaN phosphatase activity. As mentioned, B06 
treatment reduced GSK3β activation by increasing the levels of its inactive form 
phosphorylated at Ser9, whereas it activated AKT signaling. Because AKT is a recognized 
prosurvival molecule that participates in neural plasticity, modulation of AKT signaling in 
animals treated with the I2-IR ligand B06 likely contributed to the favorable effects on 
cognition observed in SAMP8 mice (Zhu et al. 2001; Sun and Nan. 2017). 
 
p-CREB controls the expression of genes related to synaptic disruption and LTP, such as 
Bdnf (Bridi et al. 2017). Neuronal growth and survival require the expression of CREB 
target genes that control various proteins, including BDNF and its receptor tropomyosin-
related kinase B (TrkB) (Zhang et al. 2012). On the one hand, treatment with the I2-IR 
ligand B06 increased nuclear p-CREB levels and increased Bdnf gene expression. On the 
other hand, B06 increased the levels of PKA, which can drive p-CREB nuclear 
translocation. Of note, PKA acts as a negative modulator of NFATc1, a transcription factor 
that regulates the transcription of genes that play crucial roles in axonal outgrowth control 
(Sheridan et al. 2002). Interestingly, I2-IR ligand treatment induced an increase in NFATc1 
phosphorylation in parallel with decreases in Il-6, Ifn-γ and Tnf-α gene expression. NFATc1 
and CaN are master regulators that control EAAT2 up- or downregulation (Su et al. 2003). 
We hypothesize that the observed changes in NFATc1 are responsible for the increase in 
EAAT2 described above. 
 
NFATc1 is dephosphorylated by CaN, which enables its nuclear translocation. Continuous 


































































abnormalities, including neuritic dystrophy, dendritic spine loss and modulation of β-
amyloid accumulation. Indeed, NFAT activity stimulates the amyloidogenic pathway (Jin et 
al. 2012; Sompol et al. 2017), and its inhibition has been found to significantly reduce β-
amyloid plaque formation in an AD mouse model (Furman et al. 2012). Therefore, a 
reduction in nuclear NFAT should have beneficial effects in senescence models, in which 
overactivation of neurodegenerative pathways is a key cause of cognitive decline (Griñán-
Ferré et al. 2015, 2016). 
 
The last finding, closely linked with the findings described above, is the implication of CaN 
in the beneficial effects of the I2-IR ligand B06 in SAMP8 mice. CaN is a multicomponent 
protein in which CaN A has phosphatase activity regulated by calcium levels (Rusnak F et 
al. 2010). Calcium dysregulation can be induced by age-related changes, such as OS and 
inflammation (Furman et al. 2014; Reese and Taglialatela. 2014). Furthermore, inhibition 
of CaN signaling produces neuroprotection in models of injury and disease (O’Donell et al. 
2016; Xiong et al. 2018), reduces neuroinflammation (Furman and Norris, 2014) and 
cognitive impairment (Liu et al. 2018), and improves synapse function (Kim et al. 2015). 
Consistent with these findings, we hypothesized that in SAMP8 mice, which are 
characterized by neuroinflammation and OS, an imbalance of calcium levels occurs, 
activating CaN A and inducing neurodegeneration. Specifically, astrocytic CaN is activated 
under inflammatory conditions and can, for example, activate GSK3β and inactivate AKT, 
influencing NMDAR-mediated axonal outgrowth (Wang et al. 2018). As stated above, the 
I2-IR ligand B06 reduced CaN A protein levels, and accordingly, we found activation of 
AKT and strong inactivation of GSK3β. 
 
Regarding the OS observations, CaN can be activated after H2O2 addition to neuronal 
cultures (Sée and Loeffler. 2001). Likewise, the reductions in OS markers after treatment 
with the I2-IR ligand B06 could have also contributed to a reduction in CaN activity. These 
findings correlate with cognitive improvement, increasing neuroprotective signaling and 
reducing tau hyperphosphorylation. Conversely, CaN A can dephosphorylate tau. However, 
the balance between tau phosphorylation and dephosphorylation is due to a shift in tau 


































































dephosphorylation of a few transcription factors, such as CREB (which blocks CREB 
translocation to the nucleus) and NFAT (which enables NFAT translocation to the nucleus). 
In both cases, the reduced synaptic and growth gene transcription necessitates plasticity, 
and the increases in the expression of proinflammatory factors participate in 
neurodegenerative processes. Moreover, hyperactivation of the phosphatase 2B (PP2B) 
domain increases BAD dephosphorylation, favoring the action of BAD as a proapoptotic 
factor (Mukherjee et al. 2010). 
 
In conclusion, the data from our study demonstrate that modulation of I2-IRs by B06 
reduces neuroinflammation, OS and CaN protein levels in SAMP8 mice. The decreases in 
CaN protein levels can explain the changes in CREB, NFATc1 and BAD phosphorylation 
levels. In addition, the decreases in CaN levels result in modification of the kinase activity 
of GSK3β and AKT, among other molecules, leading to reduced tau hyperphosphorylation 
and preventing cognitive decline in SAMP8 mice. Collectively, our findings provide 
evidence that the CaN pathway is a critical component of the neuroprotective effects of I2-
IR ligands on SAMP8 model mice, providing insight into several molecular modifications 
observed after I2-IR ligand treatment. In the future, a deeper knowledge of the role of the I2-
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Figure 1. Scheme for NORT (A) and OFT (B) experimental paradigms. The I2-IR ligand 
improved the novel object recognition abilities (measured as Discrimination Index, DI) in 
SAMP8 treated with B06 at 5 mg/Kg/day (B06 5mg/kg) in comparison with the SAMP8 
Control both in summary short-term memory (C) and summary long-term memory (D). In 
the Open Field Test (OFT) 12-month-old SAMP8 treated with B06 at 5 mg/Kg/day (B06 
5mg/kg) presented a significant increase in the distance traveled (E), the percentage of time 
spent in Center zone (F) and the number of Rearings (G). Values represented are mean ± 
Standard error of the mean (SEM); n = 15 (Control n = 8, B06 n = 7); *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001 vs. Control.  
 
Figure 2. Treatment with the I2-IR ligand B06 resulted in significant differences in the 
amyloid processing and Αβ degradation pathway between the 12-month-old control 
SAMP8 (Control) and the SAMP8 treated with B06 at 5 mg/Kg/day (B06 5mg/kg). 
Representative western blot for sAPPα and sAPPβ protein levels and quantification (A, B). 
Values in bar graphs were adjusted to 100% for the protein of control SAMP8 (Control). 
Representative gene expression for Adam10, Ide and Nep (C). Gene expression levels were 
determined by real-time PCR. Values are the mean ± Standard error of the mean (SEM);  
(n= 3-5 animals per group); *p<0.05; **p<0.01 vs. Control.  
 
Figure 3. The I2-IR treatment mediated a significant decrease in Tau phosphorylation and 
the implicated kinases in 12-month-old SAMP8 treated with B06 at 5 mg/Kg/day (B06 
5mg/kg) when compared to control SAMP8 (Control). Representative western blot for ratio 
p-Tau (Ser396 and Ser404), Ratio p-GSK3β (Ser9), Ratio p-CDK5, p25/35 and 


































































SAMP8 (Control). Values are the mean ± Standard error of the mean (SEM); (n= 3-5 
animals per group); *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs. Control.  
 
Figure 4. Changes in NMDARs, neuronal plasticity and Kinase pathways induced by I2-IR 
ligand B06 in 12-month-old SAMP8 after treatment at 5 mg/Kg/day (B06 5mg/kg) in 
comparison with 12-month-old control SAMP8 (Control). Representative western blot for 
NMDAR2B, NMDAR2A, Ratio p-NMDAR2B (Tyr1472). Ratio p-CREB in nucleus 
protein levels and quantification (A-D). Representative Western blot for kinases PKA, 
Ratio p-AKT and quantification (E, F). Values in bar graphs were adjusted to 100% for the 
protein of control SAMP8 (Control). Representative gene expression for Bdnf (G). Gene 
expression levels were determined by real-time PCR. Values are the mean ± Standard error 
of the mean (SEM); (n= 3-5 animals per group); *p<0.05; **p<0.01; ***p<0.001 vs. 
Control. 
 
Figure 5. Treatment with the I2-IR ligand B06 suppressed apoptosis by inhibiting the 
implicated apoptotic factors in 12-month-old SAMP8 treated with B06 at 5 mg/Kg/day 
(B06 5mg/kg) as compared to control SAMP8 (Control). Representative western blot for 
caspase-3, Bax, BCL-2, Ratio p-BAD (Ser136) and quantification (A-D). Values in bar 
graphs were adjusted to 100% for the protein of control SAMP8 (Control). Values are the 
mean ± Standard error of the mean (SEM); (n= 3-5 animals per group); *p<0.05; **p<0.01 
vs. Control.  
 
Figure 6. I2-IR ligand, B06, attenuated neuroinflammation and OS state in 12-month-old 
SAMP8 treated mice at 5 mg/Kg/day (B06 5mg/kg) when compared to the control SAMP8 
(Control). Representative western blot for GFAP, GLT-1/EAAT-2 (A-B). Representative 
gene expression for inflammatory markers such as Il-6, Il-18 Il-1β, Ifn-γ, Tnf-α and Cxcl-
10 (C) and OS markers such as Hmox1, iNOS, Nrf1 and Aldh2 (E). Quantification of 
Intracellular H202 (μM) (D). Gene expression levels were determined by real-time PCR. 
Values in bar graphs were adjusted to 100% for the protein of control SAMP8 (Control). 
Representative images for GFAP (F) and S100A9 immunostaining (F) and quantifications 


































































immunohistochemical images is 200 μm. Values are the mean ± Standard error of the mean 
(SEM); (n= 3-5 animals per group); *p<0.05; ***p<0.001 vs. Control.  
 
Figure 7. Modulation of CaN signaling after B06 treatment in 12-month-old SAMP8 
treated mice at 5 mg/Kg/day (B06 5mg/kg). Representative western blot for CaN A, ratio p-
NFATc1/NFATc1 and quantification (A, B). Values in bar graphs were adjusted to 100% 
for protein of control SAMP8 (Control). Values are the mean ± Standard error of the mean 
(SEM); (n= 3-5 animals per group); *p<0.05; **p<0.01 vs. Control. 
 
Figure 8. Graphical Abstract showing molecular changes in CaN signaling after treatment 












































































































































































































































































































Ratio p-Tau (Ser 396) 
****
Figure 3
p-TAU (Ser396) 55 kDa
Tau Total 50 kDa
GAPDH 37 kDa
A
p-TAU (Ser404) 55 kDa
Tau Total 50 kDa
GAPDH 37 kDa
B
p-GSK3β (Ser9) 47 kDa
GAPDH 37 kDa
GAPDH 37 kDa
GSK3β Total 47 kDa
C
Actin p-CDK5 33 kDa



















Ratio p-Tau (Ser 404) 
***
β-Actin 43 kDa





































































































































line figure 4 Click here to access/download;line figure;Figure 4_j.pdf






















































p-BAD (Ser 136) 23 kDa
BAD Total 23 kDa


























































colour figure 6 Click here to access/download;colour figure;Figure_6_j.pdf
Figure 7  
Calcineurin A 62 kDa




p-NFATc1 (Ser172) 120 kDa
GAPDH 37 kDa
B
























































































Figure 8  
EAAT2
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Table 1. Antibodies used in Western blot studies. 
 
Antibody Host Source/Catalog WB dilution 
AKT Rabbit Cell Signaling/#9272 1:1000 
Bad Mouse Santa Cruz/sc-8044 1:1000 
Bax Rabbit Cell signaling/#2772 1:1000 
Bcl-2 Rabbit Cell Signaling/#2870 1:1000 
Calcineurin A Rabbit  BioRad/VPA00329 1:1000 
Calpain Mouse BioRad/AHP2443 1:1000 
CaMKII Rabbit Abcam/ab52476 1:1000 
Caspase-3 Rabbit Cell Signaling/#9662 1:1000 
Cdk5 Rabbit  Santa Cruz/sc-173 1:1000 
CREB (48H2) Rabbit  Cell Signaling/#9197 1:1000 
EAAT2 Mouse Santa Cruz/sc-365634 1:1000 
GFAP Rabbit Gene Tex/GTX100850 1:1000 
GSK-3β Rabbit  Cell Signaling/#9315S 1:1000 
NFATc1 Rabbit St John’s/STJ24751 1:1000 
NMDA2A Mouse  Santa Cruz/sc-515148 1:1000 
NMDA2B Mouse Santa Cruz/sc-365597 1:1000 
P35/p25 Rabbit Cell Signaling/#C64B10 1:1000 
pAKT (Ser473) Rabbit Cell Signaling/#4060 1:1000 
pBAD (Ser136) Rabbit Cell Signaling/#4366S 1:500 
pCaMKII (Thr286) Rabbit SAB/#11287 1:1000 
pCdk5 (Y15) Rabbit Abcam/ab63550 1:1000 
pCREB (Ser133) Rabbit Cell Signaling/#9198 1:1000 
P-p44/42 (T202/Y204) Rabbit Cell Signaling/#9101 1:1000 
p-GSK-3beta Rabbit Cell Signaling/#9336 1:1000 
PKA Mouse Santa Cruz/sc-28315 1:1000 
p-NFAT (Ser172) Rabbit Invitrogen/PA5-64696 1:500 
pNMDAR2B (Tyr1472) Rabbit Invitrogen/OPA1-04116 1:1000 
p-Tau Ser396 Rabbit Invitrogen/44-752G 1:1000 
p-Tau Ser404 Rabbit Invitrogen/44-758G 1:1000 
sAPPα Rabbit Covance/SIG-39139-005 1:2000 
sAPPβ Rabbit Covance/SIG-39138-05 1:2000 
Tau total  Mouse Invitrogen/AHB0042 1:1000 
table 1 Click here to access/download;table;Table A1.pdf
 
 
TBP Mouse Abcam/ab51841 1:1000 
Actin Mouse Invitrogen/MA5-15739 1:2000 
GAPDH Mouse Millipore/MAB374 1:5000 
Goat-anti-mouse HRP 
conjugated 
 Biorad/170-5047 1:2000 
Goat-anti-rabbit HRP 
conjugated 







Table 2. Reagents used in IHC studies. 
Antibody Host Source/Catalog IHC dilution 
GFAP Rabbit DAKO/Z0334 1:400 
S100A9 Mouse R&D Systems/AF2065 1:400 
Alexa Fluor 594  
Goat anti-mouse IgM 
 Invitrogen/A21044 1:1000 
Alexa Fluor 488 
Rabbit anti-goat IgG 
 Invitrogen/A11078 1:400 
Hoechst 33258 solution   Sigma-Aldrich/94403  
 
table 2 Click here to access/download;table;Table 2.docx
Table 3. Primers and probes used in qPCR studies. 
SYBR Green primers 
Target 
 
Product size (bp) Forward primer (5’-3’) Reverse primer (5’-3’) 
Ide 128 GCAACACCATACCCTGCTCT TCCACATAAGCAAACGGGCT 
Adam10 125 GGGAAGAAATGCAAGCTGAA CTGTACAGCAGGGTCCTTGAC 
Cxcl10 72 GGCTAGTCCTAATTGCCCTTGG TTGTCTCAGGACCATGGCTTG 
Il-6 189 ATCCAGTTGCCTTCTTGGGACTGA TAAGCCTCCGACTTGTGAAGTGGT 
Il-18 151 GTTTACAAGCATCCAGGCACAG GAAGGTTTGAGGCGGCTTTC 
Il-1β 179 TGTGAAATGCCACCTTTTGA GGTCAAAGGTTTGGAAGCAG 
Ifn-γ 87 CCTTCTTCAGCAACAGCAAGGCG CTTGGCGCTGGACCTGTGGG 
Tnf-α 157 TCGGGGTGATCGGTCCCCAA TGGTTTGCTACGACGTGGGCT 
iNOS 125 GGCAGCCTGAGAGACCTTTG GGAAGCGTTTCGGGATCTGAA 
Nrf1 114 AGCACGGAGTGACCCAAAC TGTACGTGGCTACATGGACCT 
Aldh2            189  GCAGGCGTACACAGAAGTGA TGAGCTTCATCCCCTACCCA 
Nep 196 TTGGGAGACCTGGCGGAAAC CATTCCTTGGACCCTCACCCC 
β-actin 190 CAACGAGCGGTTCCGAT GCCACAGGTTCCATACCCA 
 
Taqman probes 
Target Product size (bp) Reference 
Hmox1 69 Mm00516005_m1 
Bdnf 71 Mm01334042_m1 




table 3 Click here to access/download;table;Table 3.docx
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